• Metabolic dysfunction and obesity are modifiable upstream drivers of chronic disease, and dietary therapy is the first-line response.
• Calorie-restricted low-fat advice is predictably ineffective, and willpower is not an adequate explanation for obesity.

Insulin and carbohydrate model

• Insulin is the dominant hormonal driver of fat storage because it promotes substrate entry into adipocytes and suppresses stored-fat release.
• Lipohypertrophy, weight gain after insulin initiation, insulin omission for weight control, and an eight-year youth cohort show the fat-storing effect of high insulin.
• High-carbohydrate diets raise glucose and insulin, enable de novo lipogenesis after glycogen capacity is filled, activate lipoprotein lipase and GLUT4, and inhibit hormone-sensitive lipase.
• A controlled feeding trial found roughly 300 kcal per day higher energy expenditure on the low-carbohydrate diet during weight-loss maintenance.

Low-carbohydrate evidence and common objections

• Seventy-one randomized low-carbohydrate versus low-fat weight-loss trials ran from 2003 to 2023, with all 39 statistically significant results favoring low carbohydrate.
• Twenty meta-analyses and umbrella reviews are further evidence that carbohydrate restriction outperforms low-fat diets for weight loss.
• A dietary requirement for 130 g of carbohydrate is unnecessary because ketones can fuel the brain and Cahill's fasted subjects tolerated profound insulin-induced hypoglycemia without symptoms.
• Nutritional ketosis differs from diabetic ketoacidosis, and SGLT2-associated euglycemic acidosis involves insulin deficiency and renal acid handling, not ketones alone.
• Routine protein restriction is unnecessary for healthy kidneys; MDRD follow-up and meta-analyses found no renal harm from higher protein intake in people without proteinuria.

Saturated fat and LDL

• A simple saturated-fat-to-LDL rule is invalid because a butter, olive-oil, and coconut-oil trial did not produce the predicted LDL response.
• LDL participates in innate immunity, and hypothyroidism, vitamin B12 deficiency, and folate deficiency can elevate LDL independently of dietary saturated fat.
• The corn-oil trial, Sydney Diet Heart Study, Minnesota Coronary Experiment, and Women's Health Initiative failed to show cardiovascular benefit from reducing saturated fat and produced adverse signals.
• Delayed publication, incomplete publication, and selective placement of statistically significant results distorted the saturated-fat evidence base.
• Reviews of the evidence available before the 1977 guidelines and later meta-analyses provide no mortality justification for reducing saturated fat.

Semaglutide and GLP-1 drugs

• STEP 1 produced an average 16.86 kg loss over 68 weeks in more than 1,300 participants, but DXA data from 95 participants attributed 39% of total loss to lean tissue.
• Trial participants received exercise counseling, yet the pivotal publications did not quantify resistance training well enough to determine its protective effect.
• SELECT regulatory data showed about a fivefold hip-fracture signal in females, and a 52-week Danish trial found lower spine and hip bone density, thinner tibial cortical bone, and rising bone resorption.
• Recent epidemiology linked GLP-1 receptor agonists with an 11% higher fragility-fracture risk in older adults, while AAOS data linked use with higher five-year osteoporosis and osteomalacia risk.
• STEP 1 follow-up participants regained about two-thirds of lost weight within 12 months after withdrawal, while STEP 2 supplied no body-composition data on regained weight.
• Blundell's mechanistic trial found semaglutide reduced unrestricted energy intake by roughly one-quarter to one-third without improving food composition.
• The gaunt facial change called "Ozempic face" is chiefly lean-tissue loss and malnutrition produced by appetite suppression.

Nutrient adequacy and tissue preservation

• A 1975 intravenous overfeeding study found that withholding nitrogen, phosphate, potassium, or sodium blocked muscle or bone formation and diverted most or all gained weight into fat.
• Bone is mineralized protein, so calcium alone is inadequate; an older-adult calcium and vitamin D trial linked the highest protein intake with increased bone mineral density.
• A 2015 phosphate trial reduced weight and waist circumference, while magnesium and potassium experiments linked mineral repletion with improved glucose regulation.
• Plant antinutrients and conversion limits reduce usable phosphorus, iron, zinc, retinol, EPA, and DHA despite their nominal presence in foods.
• Animal foods supply highly bioavailable micronutrients and higher-scoring protein, making protein quality important during drug-induced appetite suppression.

Clinical conclusion

• A low-carbohydrate, nutrient-dense, mostly animal-based diet with adequate protein is the preferred route to lower insulin, preserve lean tissue, and stimulate natural satiety.
• Resistance training and sufficient protein can mitigate muscle and bone loss, but adopting them may also remove the need for indefinite injectable therapy.
• Semaglutide can produce substantial weight loss, but patients should receive full informed consent about lean-tissue loss, skeletal risks, nutritional shortfalls, indefinite use, and weight regain after withdrawal.

References

• [00:04] Prevalence of lipohypertrophy in insulin-treated diabetes patients: A systematic review and meta-analysis — https://doi.org/10.1111/jdi.12742
• [00:06] Glycogen storage capacity and de novo lipogenesis during massive carbohydrate overfeeding in man — https://doi.org/10.1093/ajcn/48.2.240
• [00:09] Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: Randomized trial — https://doi.org/10.1136/bmj.k4583
• [00:12] Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids — https://doi.org/10.17226/10490
• [00:18] Effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease — https://doi.org/10.1056/NEJM199403313301301
• [00:19] Effect of a very low-protein diet on outcomes: Long-term follow-up of the Modification of Diet in Renal Disease Study — https://doi.org/10.1053/j.ajkd.2008.08.009
• [00:19] Changes in Kidney Function Do Not Differ between Healthy Adults Consuming Higher- Compared with Lower- or Normal-Protein Diets: A Systematic Review and Meta-Analysis — https://doi.org/10.1093/jn/nxy197
• [00:20] Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women — https://doi.org/10.1136/bmjopen-2017-020167
• [00:23] Corn Oil in Treatment of Ischaemic Heart Disease — https://doi.org/10.1136/bmj.1.5449.1531
• [00:23] Use of dietary linoleic acid for secondary prevention of coronary heart disease and death — https://doi.org/10.1136/bmj.e8707
• [00:24] Re-evaluation of the traditional diet-heart hypothesis: Analysis of recovered data from Minnesota Coronary Experiment — https://doi.org/10.1136/bmj.i1246
• [00:24] Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial — https://doi.org/10.1001/jama.295.6.655
• [00:26] Evidence from randomised controlled trials did not support the introduction of dietary fat guidelines in 1977 and 1983 — https://doi.org/10.1136/openhrt-2014-000196
• [00:27] Reduction in saturated fat intake for cardiovascular disease — https://doi.org/10.1002/14651858.CD011737.pub3
• [00:28] Once-Weekly Semaglutide in Adults with Overweight or Obesity — https://doi.org/10.1056/NEJMoa2032183
• [00:29] Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study — https://doi.org/10.1210/jendso/bvab048.030
• [00:30] Australian Product Information: Wegovy — https://www.tga.gov.au/sites/default/files/2024-09/auspar-wegovy-01-240904-pi.pdf
• [00:31] Once-weekly semaglutide versus placebo in adults with increased fracture risk: A randomised, double-blinded, two-centre, phase 2 trial — https://doi.org/10.1016/j.eclinm.2024.102624
• [00:32] GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes — https://doi.org/10.1210/clinem/dgag056
• [00:32] Studies explore GLP-1 receptor agonist use and its impact on long-term musculoskeletal health — https://aaos-annualmeeting-presskit.org/2026/research-news/studies-explore-glp-1-receptor-agonist-use-and-its-impact-on-long-term-musculoskeletal-health/
• [00:33] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension — https://doi.org/10.1111/dom.14725
• [00:33] Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes: STEP 2 — https://doi.org/10.1016/S0140-6736(21)00213-0
• [00:34] Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity — https://doi.org/10.1111/dom.12932
• [00:39] Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older — https://doi.org/10.1056/NEJM199709043371003
• [00:40] Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women — https://doi.org/10.1093/ajcn/75.4.773
• [00:41] Effect of phosphorus supplementation on weight gain and waist circumference of overweight/obese adults: A randomized clinical trial — https://doi.org/10.1038/nutd.2015.38
• [00:43] Differences among total and in vitro digestible phosphorus content of plant foods and beverages — https://doi.org/10.1053/j.jrn.2011.04.004